enVVeno participates in ‘What This Means’ segment on Trump’s CVI diagnosis

enVVeno Medical (NVNO) participated in a Virtual Investor “What This Means” segment entitled, “enVVeno Medical – Making Veins Work Again – How President Trump’s CVI Diagnosis is Raising Awareness.” Rob Berman, CEO and Dr. Marc Glickman, CMO discussed the progressive nature of chronic veinous insufficiency and whether President Trump may one day be a candidate for the VenoValve following U.S. Food and Drug Administration approval. The Company estimates that there are approximately 2.5M patients in the U.S. that could be candidates for the VenoValve. The Company has submitted a pre-market authorization application for the VenoValve to the FDA, with a decision anticipated in the second half of 2025.